
Opinion|Videos|July 29, 2024
Unmet Needs and Starting Advanced Treatment in Inflammatory Bowel Disease
Silvio Danese, MD, PhD; Bruce Sands, MD, and Jean-Frederic Colombel, MD, highlight the common practice in many community settings of treating inflammatory bowel disease (IBD) with corticosteroids, with or without 5-aminosalicylic acid, and cycling patients through this regimen for prolonged periods, while emphasizing the significant impact and toxicities associated with this treatment approach.
Advertisement
Episodes in this series

- When should clinicians start thinking about starting advanced targeted therapies for patients with UC or CD?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Q&A: Intensive LDL Lowering and Cardiovascular Prevention Strategies, With Lawrence Leiter, MD
2
2 Out of 3 Patients with Atopic Dermatitis Are Being Misdiagnosed
3
Evaluating Clinical and Real-World Evidence in Hypercortisolism
4
Synergy Between Metreleptin and GLP-1 Receptor Agonists in Lipodystrophy Real-World Data Suggest
5























































































